Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles

Inclusion Criteria:

* Women who have a history of infertility ≥1year.
* Ages between 20 and 35 years.
* Patients diagnosed with PCOS according to the revised 2003 Rotterdam consensus and met 2 out of 3 criteria as follows (Rotterdam, 2004):

  * Oligo- and/or anovulation.
  * Biochemical and/or clinical evidence of hyperandrogenism.
  * Polycystic ovarian morphology on ultrasound (the presence of ≥12 antral follicles (≤9mm) and/or ovarian volume \>10mL on transvaginal ultrasonographic scanning).

Other etiologies of hyperandrogenism and ovulatory dysfunction will be excluded, including androgen-secreting tumors, congenital adrenal hyperplasia, hyperprolactinemia and thyroid disease.

Exclusion Criteria:

* Endometriosis grade 3 or higher.
* Documented ovarian failure, including basal FSH above 10IU/L.
* Clinically significant systemic disease, or other endocrine disorders, including 21-hydroxylase deficiency, uncorrected thyroid disease or suspected Cushing's syndrome.
* Patients who in the previous 3 months received hormonal treatments or other medications known to affect reproductive function, including oral contraceptives and GnRH agonists.
* Documented history of ovarian surgery including laparoscopic ovarian drilling, ovarian endometrioma stripping and unilateral oophorectomy
* Previous diagnosis of congenital (septate uterus, duplex uterus, uterus bicornis and uterus unicornis) or acquired (intrauterine adhesion, submucosal myomas and adenomyosis) uterine anomalies
* History of recurrent spontaneous abortion, defined as three or more previous spontaneous pregnancy losses
* Abnormal chromosomal karyotype in either of the partners.
* Inability to comply with the study procedures.